PT1218352E - Novos derivados de benzimidazolona tendo receptores com afinidade mista para os receptores de serotonina e dopamina - Google Patents

Novos derivados de benzimidazolona tendo receptores com afinidade mista para os receptores de serotonina e dopamina

Info

Publication number
PT1218352E
PT1218352E PT00965975T PT00965975T PT1218352E PT 1218352 E PT1218352 E PT 1218352E PT 00965975 T PT00965975 T PT 00965975T PT 00965975 T PT00965975 T PT 00965975T PT 1218352 E PT1218352 E PT 1218352E
Authority
PT
Portugal
Prior art keywords
receptors
serotonin
benzimidazolone derivatives
dopamine
mixed affinity
Prior art date
Application number
PT00965975T
Other languages
English (en)
Inventor
Maura Bignotti
Enzo Cereda
Giovanni Battista Schiavi
Original Assignee
Boehringer Ingelheim Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Italia filed Critical Boehringer Ingelheim Italia
Publication of PT1218352E publication Critical patent/PT1218352E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT00965975T 1999-09-22 2000-09-12 Novos derivados de benzimidazolona tendo receptores com afinidade mista para os receptores de serotonina e dopamina PT1218352E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI001964A IT1313625B1 (it) 1999-09-22 1999-09-22 Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.

Publications (1)

Publication Number Publication Date
PT1218352E true PT1218352E (pt) 2004-09-30

Family

ID=11383635

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00965975T PT1218352E (pt) 1999-09-22 2000-09-12 Novos derivados de benzimidazolona tendo receptores com afinidade mista para os receptores de serotonina e dopamina

Country Status (16)

Country Link
US (1) US6281218B1 (pt)
EP (1) EP1218352B1 (pt)
JP (2) JP4989002B2 (pt)
AR (1) AR025739A1 (pt)
AT (1) ATE266644T1 (pt)
AU (1) AU7653700A (pt)
CA (1) CA2381819C (pt)
CO (1) CO5210864A1 (pt)
DE (1) DE60010732T2 (pt)
DK (1) DK1218352T3 (pt)
ES (1) ES2220541T3 (pt)
IT (1) IT1313625B1 (pt)
MX (1) MXPA02001986A (pt)
PE (1) PE20010600A1 (pt)
PT (1) PT1218352E (pt)
WO (1) WO2001021593A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US7033345B2 (en) * 2002-05-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Deflectable microimplant delivery system
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20050215589A1 (en) * 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
CA2537364A1 (en) * 2003-09-03 2005-03-10 Galapagos Nv Imidazo[1,5-a]pyridine or imidazo[1,5-a]piperidine derivatives and their use for the preparation of medicament against 5-ht2a receptor-related disorders
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
EP1807422B1 (en) * 2004-11-05 2009-09-02 Theravance, Inc. 5-ht4 receptor agonist compounds
WO2006052889A2 (en) * 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
US7419989B2 (en) * 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
CN101163701A (zh) * 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
JP5086248B2 (ja) * 2005-06-07 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニストとしてのベンゾイミダゾロン−カルボキサミド化合物
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
US20090176698A1 (en) * 2006-02-20 2009-07-09 Boehringer Ingelheim International Gmbh Benzimidazolone Derivatives for the Treatment of Urinary Incontinence
JP2009536176A (ja) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
AR062320A1 (es) * 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) * 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
WO2008061968A1 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh Benzimidazolone derivates in the treatment of pulmonary arterial hypertension
ATE524446T1 (de) * 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
JP5087011B2 (ja) * 2007-01-23 2012-11-28 馨 井上 眼疾患モデル用非ヒト動物
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009092720A1 (en) * 2008-01-24 2009-07-30 Neurosearch A/S 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.

Also Published As

Publication number Publication date
EP1218352A1 (en) 2002-07-03
JP4989002B2 (ja) 2012-08-01
AR025739A1 (es) 2002-12-11
PE20010600A1 (es) 2001-06-04
ITMI991964A0 (it) 1999-09-22
CA2381819A1 (en) 2001-03-29
DK1218352T3 (da) 2004-06-28
DE60010732T2 (de) 2005-05-25
CO5210864A1 (es) 2002-10-30
CA2381819C (en) 2007-03-13
EP1218352B1 (en) 2004-05-12
AU7653700A (en) 2001-04-24
JP2003509496A (ja) 2003-03-11
DE60010732D1 (de) 2004-06-17
ATE266644T1 (de) 2004-05-15
JP2012067105A (ja) 2012-04-05
IT1313625B1 (it) 2002-09-09
US6281218B1 (en) 2001-08-28
WO2001021593A1 (en) 2001-03-29
ES2220541T3 (es) 2004-12-16
ITMI991964A1 (it) 2001-03-22
MXPA02001986A (es) 2002-10-31

Similar Documents

Publication Publication Date Title
PT1218352E (pt) Novos derivados de benzimidazolona tendo receptores com afinidade mista para os receptores de serotonina e dopamina
AU4337699A (en) Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5HT4 receptors
DK1102762T3 (da) 2-substituerede-1-piperidylbenzimidazolforbindelser som ORL1-receptoragonister
EE200300296A (et) Asendatud püridoindoolid kui serotoniini agonistid ja antagonistid ning nende kasutamine
EE200100403A (et) Indooli derivaadid ja nende kasutamine MCP-1 antagonistidena
NO20035490D0 (no) Substituerte imidazolderivater med agonist-liknende virkning på alfa 2B eller 2B/2C adrenerge reseptorer
EE200300191A (et) Alfa-arüül-etanoolamiinid ja nende kasutamine beeta-3 adrenergiliste retseptorite agonistidena
BR1100460A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-ht1
PT1189916E (pt) N-pirazole agonistas do receptor a2a
DE69934881D1 (de) Selective il-2 agonisten und antagonisten
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
EE04141B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga
EE9600095A (et) Indooli derivaadid kui 5-HT agonistid
DE69506826T2 (de) 5-HT4 Rezeptoragonisten
EE9800417A (et) Dopamiini D4 retseptorite bensoksasinoonantagonistid
DE69740099D1 (de) Transdermale zusammenstellung mit serotoninrezeptor-antagonist
NO963331D0 (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
DK0912556T3 (da) Indolinderivater, der er anvendelige som 5-HT-2C-receptorantagonister
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
MXPA03002370A (es) Nuevos derivados bencimidazolona n,n'-disustituidos con afinidad en los receptores de serotonina y dopamina.
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
NO993172D0 (no) Sulfonamid-forbindelser med 5-HT-reseptor-aktivitet
NO20006041D0 (no) N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer
EE04142B1 (et) Selektiivse 5-HT 1A antagonisti kombinatsioon selektiivse h5-HT 1B antagonisti või osalise agonistiga